Hubei Hendi Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this announcement is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
On June 1, 2026, the Company held the 20th meeting of the second Board of Directors to review the proposal on the 2026 annual compensation plan for directors and senior management. All directors abstained from voting, and the proposal will be submitted directly to the Company's first extraordinary general meeting of shareholders in 2026 for consideration.
In accordance with the "Guidelines for the Governance of Listed Companies," "Shenzhen Stock Exchange Stock Listing Rules," and other relevant laws, regulations, normative documents, and the Company's Articles of Association and "Compensation Management System for Directors and Senior Management," the Board of Directors' Compensation and Assessment Committee has formulated the "Compensation and Performance Assessment Plan for Directors and Senior Management (2026)." The specific plan is as follows:
I. Applicable Objects
Directors and senior management during the term of 2026.